Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.820 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer Patients
 
Via Benzinga
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
From Coherus BioSciences, Inc.
Via GlobeNewswire
Biotech Alert: Searches Spiking For These Stocks Today - Friday, June 2
Various names in the biotech sector are seeing a substantial increase in search activity today. Such names include the likes of Akebia Therapeautics, Corvus Pharmaceuticals, and Mirati Therapeutics. 
Via Talk Markets
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'
One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug... 
Via Benzinga
Why Is AbbVie Stock Trading Down Today?
AbbVie Inc. (NYSE: ABBV) shares are trading lower Thursday after Coherus BioSciences Inc. 
Via Benzinga
Looking Into Coherus BioSciences's Return On Capital Employed
 
Via Benzinga
6 Analysts Have This to Say About Coherus BioSciences
 
Via Benzinga
Coherus BioSciences Earnings Preview
 
Via Benzinga
Coherus BioSciences's Return On Capital Employed Overview
 
Via Benzinga
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
List price of $995 per carton for two 40 mg/0.8 mL autoinjectors 
From Coherus BioSciences, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That Could Blast Off In May
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
From Coherus BioSciences, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 63 companies hit new 52-week lows. 
Via Benzinga
Coherus Prices Public Offering of Common Stock
From Coherus BioSciences, Inc.
Via GlobeNewswire
Vodafone, Calliditas Therapeutics, Rumble And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Coherus Announces Proposed Public Offering of Common Stock
From Coherus BioSciences, Inc.
Via GlobeNewswire
Gold Edges Higher; PayPal Shares Tumble Despite Upbeat Earnings
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 50 points on Tuesday. The Dow traded down 0.01% to 33,616.00 while the NASDAQ fell 0.43% to... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday! 
Via InvestorPlace
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences to Present at Upcoming Investor Conferences in May
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
Analyst Sees A Multibagger, Initiates Coverage On This 'Top Notch Biosimilar Business'
Truist initiated coverage on Coherus BioSciences Inc (NASDAQ: CHRS) with a Buy rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
 
Via Benzinga
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
 
Via Benzinga
PVH, First Republic Bank And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.